Literature DB >> 18626265

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Bruce J Kinon1, Jan Volavka, Virginia Stauffer, Sara E Edwards, Hong Liu-Seifert, Lei Chen, David H Adams, Jean-Pierre Lindenmayer, Joseph P McEvoy, Peter F Buckley, Jeffrey A Lieberman, Herbert Y Meltzer, Daniel R Wilson, Leslie Citrome.   

Abstract

The objective of this study was to assess the dose-response relationship of standard and higher doses of olanzapine in a randomized, double-blind, 8-week, fixed-dose study comparing olanzapine 10 (n = 199), 20 (n = 200), and 40 mg/d (n = 200) for patients with schizophrenia or schizoaffective disorder and suboptimal response to current treatment. Patients meeting criteria for antipsychotic treatment resistance were excluded. Dose-response relationship was assessed by linear regression analysis with log-transformed dose (independent variable) and Positive and Negative Syndrome Scale (PANSS) total score (dependent variable). There were no significant dose group differences in patients completing the study (overall, 67.8%). All dose groups showed statistically significant improvement in PANSS total scores from baseline to end point without significant dose-response relationship (P = 0.295). Post hoc analysis of response showed significant interaction between baseline PANSS and dose (P = 0.023), indicating better response at higher doses for patients with higher baseline PANSS. There was a significant dose response for mean change in weight (P = 0.003) with significant difference between the 10- and 40-mg-dose groups (P = 0.002; 1.9 [10 mg/d], 2.3 [20 mg/d], and 3.0 kg [40 mg/d]). There was a significant dose response for change in prolactin (P < 0.001) with a significant difference between each group (-10.5 [10 mg/d], -1.7 [20 mg/d], and 4.9 ng/mL [40 mg/d]; P < or = 0.018). Over 8 weeks, non-treatment-resistant patients with schizophrenia or schizoaffective disorder responded to all 3 doses of olanzapine, without a statistically significant dose-response relationship, suggesting that for many patients with schizophrenia or schizoaffective disorder, particularly those who are mildly or moderately ill, 10 mg/d should be the initial dose of choice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626265     DOI: 10.1097/JCP.0b013e31817e63a5

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.

Authors:  Shubhra Mace; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

Review 2.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

3.  A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.

Authors:  Christian Schmidt-Kraepelin; Sandra Feyerabend; Christina Engelke; Mathias Riesbeck; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Pablo-Emilio Verde; Henrike Kolbe; Christoph U Correll; Stefan Leucht; Stephan Heres; Michael Kluge; Christian Makiol; Andrea Neff; Christina Lange; Susanne Englisch; Mathias Zink; Berthold Langguth; Timm Poeppl; Dirk Reske; Euphrosyne Gouzoulis-Mayfrank; Gerhard Gründer; Alkomiet Hasan; Anke Brockhaus-Dumke; Markus Jäger; Jessica Baumgärtner; Thomas Wobrock; Joachim Cordes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-09-05       Impact factor: 5.270

Review 4.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

5.  Placebo response in antipsychotic clinical trials: a meta-analysis.

Authors:  Bret R Rutherford; Emily Pott; Jane M Tandler; Melanie M Wall; Steven P Roose; Jeffrey A Lieberman
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

6.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

7.  Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Authors:  Jan Volavka; Pál Czobor; Leslie Citrome; Richard A Van Dorn
Journal:  CNS Spectr       Date:  2013-11-28       Impact factor: 3.790

8.  Comparative effectiveness research for antipsychotic medications: how much is enough?

Authors:  David O Meltzer; Anirban Basu; Herbert Y Meltzer
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

Review 9.  Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.

Authors:  Shubhra Mace; David Taylor
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

10.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.